ESR1 and breast carcinoma: Our findings validate previous research showing that SEMA3C knockdown inhibits the proliferation of ER+ breast cancer cells, and extends these insights by demonstrating that SEMA3C is an autocrine growth factor that stimulates the growth of ER+ cell lines.